Genus PLC Directorate Appointment (2951R)
29 Junio 2020 - 1:00AM
UK Regulatory
TIDMGNS
RNS Number : 2951R
Genus PLC
29 June 2020
For Immediate Release 29 June 2020
Genus plc
('Genus', or the 'Company')
Appointment of Non-Executive Director and Chairman Designate
Genus plc (LSE: GNS), a leading global animal genetics company,
announces that Iain Ferguson has been appointed by the Board as an
Independent Non-Executive Director with effect from 1 July 2020,
and will succeed Bob Lawson as Chairman of the Company at the
conclusion of the Company's next Annual General Meeting ('AGM') in
November 2020. Iain has been appointed as a member of the
Nominations and Remuneration Committees, and will become Chair of
the Nominations Committee upon Bob Lawson's retirement.
Iain brings extensive Board and governance experience relevant
to Genus, as well as strong commercial, science and agribusiness
expertise across a range of industries, with a particular focus on
consumer goods and food. Iain is currently Chairman of Crest
Nicholson Holdings plc and a Non-Executive Director of Personal
Assets Trust plc, and was previously the Senior Independent
Director of the animal genetics company Sygen International plc
until 2006, when it was acquired by Genus. He was Chairman of
Stobart Group Ltd and Senior Independent Director of Balfour Beatty
plc until 2019 and Chairman of Berendsen plc until 2017.
Ia in joined Unilever plc, one of the world's largest Consumer
Goods Groups, in 1977 and built his career in a variety of roles
including General Manager, Unilever AgriBusiness, Executive Chair,
Unilever Plantations and Plant Sciences Group, and Senior Vice
President, Corporate Development, before joining Tate & Lyle
plc as Chief Executive in 2003.
Iain's appointment follows an extensive search process using an
external search agency.
Commenting on the appointment, Lesley Knox, the Company's Senior
Independent Director who led the planned succession process, said,
"For over a decade, Bob Lawson has led the successful
transformation of Genus to become a world leader in the provision
of elite bovine and porcine genetics and related services. I am
delighted that Iain has agreed to join Genus and transition into
the Chairman role. I believe that Iain brings the right mix of
Board experience, international exposure and business skills to
maintain the continued growth of the Company and its seamless
execution on strategy. The transition period prior to the AGM will
enable Iain to gain a strong understanding of the Company's
business before becoming the Chairman in November."
Iain Ferguson added, "I am delighted to have been appointed as a
Director and Chairman-designate of Genus. I look forward to working
with the Chairman, Bob Lawson, the Board, the executive committee
and the rest of the Genus team on the opportunities ahead for this
great Company."
Bob Lawson, Chairman of Genus, commented "Genus is an
outstanding company and one that I have been extremely proud to
have worked for. I look forward to assisting Iain in understanding
the Company's operations and wish him every success as he sets out
to lead Genus through the next stage of our growth."
Genus Tel: +44(0)1256
345970
Bob Lawson, Chairman
Stephen Wilson, Chief Executive
Buchanan Tel: +44(0)207 466
5000
Charles Ryland /Chris Lane
This announcement is available on the Genus website
www.genusplc.com
About Genus
Genus is a world-leading animal genetics company. Genus creates
advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming
and food producers. Its technology is applicable across livestock
species and is currently commercialised by Genus in the dairy, beef
and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries
under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs)
and comprise semen, embryos and breeding animals with superior
genetics to those animals currently in farms. Genus's customers'
animals produce offspring with greater production efficiency, and
quality, and use these to supply the global dairy and meat supply
chains.
The Group's competitive edge has been created from the ownership
and control of proprietary lines of breeding animals, the
biotechnology used to improve them and its global supply chain,
technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus
companies operate in over twenty-five countries on six continents,
with research laboratories located in Madison, Wisconsin, USA.
Regulatory Notes
Details of any payments to be made to Iain Ferguson will be
disclosed in full in the Company's 2020 Directors' Remuneration
Report. Any such terms will be consistent with the Company's
approved Directors' Remuneration Policy.
This announcement is made in accordance with Listing Rule
9.6.11R. There are no matters to be disclosed in connection with
Listing Rule 9.6.13R (2) - (6). The person responsible for making
this announcement on behalf of the Group is Dan Hartley (General
Counsel and Company Secretary).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAEANKPAEKEEFA
(END) Dow Jones Newswires
June 29, 2020 02:00 ET (06:00 GMT)
Genus (LSE:GNS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Genus (LSE:GNS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024